XML 60 R54.htm IDEA: XBRL DOCUMENT v3.26.1
Reportable Segments and Geographic Information - Schedule of Information Regarding Operations and Assets for Operating Segments (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Segment Reporting Information [Line Items]          
Revenue $ 85,389,000 $ 81,803,000 $ 156,527,000 $ 155,266,000  
Cost of revenue 59,710,000 47,368,000 109,358,000 92,485,000  
Research and development 14,554,000 13,480,000 28,730,000 25,875,000  
Selling and Marketing Expense 15,228,000 12,286,000 27,449,000 20,751,000  
General and Administrative Expense 27,195,000 26,392,000 54,879,000 51,683,000  
Operating loss (36,073,000) (19,713,000) (70,695,000) (39,508,000)  
Less (add):          
Equity-based compensation 8,624,000 10,039,000 18,514,000 20,589,000  
Amortization of intangible assets 2,603,000 1,990,000 4,634,000 3,980,000  
Interest income (6,404,000) (8,091,000) (15,055,000) (16,109,000)  
Interest expense 59,000 17,000 76,000 31,000  
Impairment loss 0 9,926,000 0 9,926,000 $ 9,900,000
Other income, net (38,000) (46,000) (48,000) (114,000)  
Loss before income taxes (29,690,000) (21,519,000) (55,668,000) (33,242,000)  
Operating Segments          
Segment Reporting Information [Line Items]          
Revenue 85,389,000 81,803,000 156,527,000 155,266,000  
Cost of revenue 58,625,000 45,631,000 106,812,000 88,968,000  
Research and development 11,418,000 10,141,000 22,057,000 19,062,000  
Selling and Marketing Expense 14,663,000 11,575,000 26,239,000 19,150,000  
General and Administrative Expense 23,089,000 22,140,000 43,498,000 43,025,000  
Operating loss (22,406,000) (7,684,000) (42,079,000) (14,939,000)  
Material Reconciling Items          
Less (add):          
Equity-based compensation 8,624,000 10,039,000 18,514,000 20,589,000  
Acquisition-related costs 17,000 0 2,649,000 0  
Acquisition-related severance 251,000 0 647,000 0  
Amortization of intangible assets 2,603,000 1,990,000 4,634,000 3,980,000  
Intangible impairment loss 2,172,000 0 2,172,000 0  
Interest income (6,404,000) (8,091,000) (15,055,000) (16,109,000)  
Interest expense 59,000 17,000 76,000 31,000  
Impairment loss 0 9,926,000 0 9,926,000  
Other income, net (38,000) (46,000) (48,000) (114,000)  
Laboratory Services          
Segment Reporting Information [Line Items]          
Revenue 85,359,000 81,803,000 156,410,000 155,266,000  
Laboratory Services | Operating Segments          
Segment Reporting Information [Line Items]          
Revenue 85,359,000 81,803,000 156,410,000 155,266,000  
Cost of revenue 58,617,000 45,631,000 106,797,000 88,968,000  
Research and development 6,823,000 5,435,000 13,284,000 10,366,000  
Selling and Marketing Expense 14,663,000 11,575,000 26,239,000 19,150,000  
General and Administrative Expense 22,698,000 21,970,000 42,750,000 42,595,000  
Operating loss (17,442,000) (2,808,000) (32,660,000) (5,813,000)  
Laboratory Services | Material Reconciling Items          
Less (add):          
Equity-based compensation 6,501,000 8,034,000 14,142,000 16,566,000  
Interest income (6,404,000) (8,091,000) (15,055,000) (16,109,000)  
Interest expense 59,000 17,000 76,000 31,000  
Laboratory Services | Precision Diagnostics | Operating Segments          
Segment Reporting Information [Line Items]          
Revenue 41,453,000 47,428,000 81,691,000 91,525,000  
Laboratory Services | Anatomic Pathology | Operating Segments          
Segment Reporting Information [Line Items]          
Revenue 37,497,000 28,122,000 62,577,000 53,422,000  
Laboratory Services | BioPharma Services | Operating Segments          
Segment Reporting Information [Line Items]          
Revenue 6,409,000 6,253,000 12,142,000 10,319,000  
Therapeutic Development          
Segment Reporting Information [Line Items]          
Revenue 30,000 0 117,000 0  
Therapeutic Development | Operating Segments          
Segment Reporting Information [Line Items]          
Cost of revenue 8,000 0 15,000 0  
Research and development 4,595,000 4,706,000 8,773,000 8,696,000  
Selling and Marketing Expense 0 (0) 0 0  
General and Administrative Expense 391,000 170,000 748,000 430,000  
Operating loss (4,964,000) (4,876,000) 9,419,000 (9,126,000)  
Therapeutic Development | Material Reconciling Items          
Less (add):          
Equity-based compensation 2,123,000 2,005,000 4,372,000 4,023,000  
Interest income 0 0 0 0  
Interest expense 0 0 0 0  
Therapeutic Development | BioPharma Services          
Segment Reporting Information [Line Items]          
Revenue $ 30,000 $ 0 $ 117,000 $ 0